Pathology: metastatic, hormone-sensitive prostate cancer;
metastatic, hormone-sensitive prostate cancer | |||||
NCI E3805 (Scott), 2017 | STAMPEDE docetaxel, 2016 | CHAARTED, 0 | GETUG-AFU 15, 2013 | ||
docetaxel plus ADT | 4 | T1 | T1 | T1 | T1 |
androgen deprivation therapy (ADT) | 0 | T0 | T0 | T0 | T0 |